Status:
NO_LONGER_AVAILABLE
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Lead Sponsor:
Basilea Pharmaceutica
Conditions:
Intrahepatic Cholangiocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patie...
Eligibility Criteria
Inclusion
- The following inclusion criteria were applied:
- all other treatment options had been exhausted
- patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib
- there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product
- patient was willing and able to provide written informed consent
- if applicable, regulatory approval by the appropriate jurisdiction was obtained
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04087876
Last Update
April 6 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.